Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Great N/R but the Shorting cartel strikes again!!

<< Previous

Bullboard Posts

Next >>

Comment by Azzak34on May 15, 2024 4:19pm

124 Views

Post# 36041925

RE:Great N/R but the Shorting cartel strikes again!!

Well said.

Pancan wanted us, Gcar wants us, FDA granted type C meeting. How is that not validation that we're knocking on the door?

And you're right. Gcar has been in the pipe for 4 or 5 months before today's announcement and I'm sure there's plenty more goings on ongoing.

<< Previous

Bullboard Posts

Next >>

Enbridge finalizes acquisition of three growing gas utilities